342 related articles for article (PubMed ID: 26881842)
1. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
[TBL] [Abstract][Full Text] [Related]
2. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.
Spinowitz B; Pecoits-Filho R; Winkelmayer WC; Pergola PE; Rochette S; Thompson-Leduc P; Lefebvre P; Shafai G; Bozas A; Sanon M; Krasa HB
J Med Econ; 2019 Jun; 22(6):593-604. PubMed ID: 30813807
[No Abstract] [Full Text] [Related]
3. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
[TBL] [Abstract][Full Text] [Related]
4. Association of anemia correction with health related quality of life in patients not on dialysis.
Alexander M; Kewalramani R; Agodoa I; Globe D
Curr Med Res Opin; 2007 Dec; 23(12):2997-3008. PubMed ID: 17958944
[TBL] [Abstract][Full Text] [Related]
5. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis.
Guedes M; Guetter CR; Erbano LHO; Palone AG; Zee J; Robinson BM; Pisoni R; de Moraes TP; Pecoits-Filho R; Baena CP
BMC Nephrol; 2020 Jul; 21(1):259. PubMed ID: 32641153
[TBL] [Abstract][Full Text] [Related]
6. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review.
Ferguson T; Xu Y; Gunasekara R; Lerner B; Macdonald K; Rigatto C; Tangri N; Komenda P
Am J Nephrol; 2015; 41(2):89-97. PubMed ID: 25721696
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
9. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
10. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
11. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
14. Is there an established hemoglobin target range for patients undergoing chronic dialysis?
Shah HH; Fishbane S
Semin Dial; 2018 Jul; 31(4):415-419. PubMed ID: 29509320
[TBL] [Abstract][Full Text] [Related]
15. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
16. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
[TBL] [Abstract][Full Text] [Related]
17. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease.
Bazeley J; Wish JB
Adv Chronic Kidney Dis; 2019 Jul; 26(4):229-236. PubMed ID: 31477253
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
19. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
Akizawa T; Tsubakihara Y; Hirakata H; Watanabe Y; Hase H; Nishi S; Babazono T; Kumagai M; Katakura S; Uemura Y; Ohashi Y;
Clin Exp Nephrol; 2016 Dec; 20(6):885-895. PubMed ID: 26779906
[TBL] [Abstract][Full Text] [Related]
20. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
